1477 Stoklara Genel Bakış Ocumension Therapeutics, iştirakleri ile birlikte Çin Halk Cumhuriyeti'nde bir oftalmik ilaç platformu şirketi olarak faaliyet göstermektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Ocumension Therapeutics Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Ocumension Therapeutics Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$4.41 52 Haftanın En Yüksek Seviyesi HK$7.54 52 Haftanın En Düşük Seviyesi HK$4.13 Beta 0.80 1 Aylık Değişim -20.68% 3 Aylık Değişim -17.26% 1 Yıllık Değişim -34.67% 3 Yıllık Değişim -73.75% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -88.08%
Son Haberler & Güncellemeler
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For Sep 21
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19 Daha fazla güncelleme görün
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For Sep 21
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results Aug 15
New minor risk - Profitability Aug 15
First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023) Aug 14
Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024 Jul 30
Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration Jul 17
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now Jun 13
Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024 May 25
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 30
Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable Apr 29
Consensus revenue estimates decrease by 14%, EPS upgraded Mar 28
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 23
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202 Mar 14
Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation Mar 14
Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024 Mar 08 Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023. Dec 14
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China Nov 30
Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China Nov 23
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023 Oct 01
Consensus revenue estimates decrease by 13% Sep 12
Consensus revenue estimates fall by 27% Aug 31
Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates Aug 29
New minor risk - Profitability Aug 28
First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022) Aug 26
Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023 Aug 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S Jul 23
We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely Jul 13
Forecast to breakeven in 2025 Jul 07
Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101 Jun 02
Consensus EPS estimates fall by 24% Apr 06
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 31
Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022 Feb 15
No longer forecast to breakeven Feb 07
Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202 Feb 04
Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China Feb 02
Now 22% undervalued Jan 30
Now 22% undervalued after recent price drop Jan 12
Less than half of directors are independent Nov 16
Board Member exercised options and sold HK$558k worth of stock Sep 25
Consensus forecasts updated Sep 02
First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021) Aug 29
Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Board Member recently sold HK$246k worth of stock Jul 24
Now 24% undervalued Jul 12
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis Jun 24
EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Jun 22
Ocumension Therapeutics Announces Executive Changes Jun 16
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China Jun 10
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant Jun 09
Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount? Jun 02
Less than half of directors are independent Apr 27
Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee Apr 09
Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee Apr 01
Consensus forecasts updated Apr 01
Forecast to breakeven in 2024 Mar 30
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 28
Consensus forecasts updated Mar 17
Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001 Mar 04
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China Mar 03
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate Jan 20
Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China Jan 05
Consensus forecasts updated Dec 18
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate Sep 27
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Sep 24
Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China Sep 15
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Aug 23
Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 in the United Kingdom Aug 04
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101 Jul 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase III Clinical Trial of OT-101 Accepted in United Kingdom May 21
Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A Multi-Regional Phase Iii Clinical Trial in the People's Republic of China for OT-101 May 12
Non-Executive Director has left the company Mar 24
Ocumension Therapeutics Announces Board Changes Mar 21
Ocumension Therapeutics, Annual General Meeting, Jun 29, 2021 Mar 20
New 90-day low: HK$22.50 Mar 10
Ocumension Therapeutics to Report Fiscal Year 2020 Results on Mar 19, 2021 Mar 10
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial Mar 05
Ocumension Therapeutics Announces Second Phase III Clinical Trial of OT-301 Approved in China Mar 04
Ocumension Therapeutics Announces Investigational New Drug Approval for Initiating A Multi-Regional Phase III Clinical Trial Feb 23
Ocumension Therapeutics Announces Phase III Clinical Trial of the Recently In-Licensed Drug Candidate of the Group Feb 10
Ocumension Therapeutics has completed a Follow-on Equity Offering in the amount of HKD 1.5876 billion. Jan 24
Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful? Jan 23
Ocumension Therapeutics announced that it expects to receive HKD 793.8 million in funding from 6 Dimensions Capital, L.P. Jan 14
New 90-day high: HK$29.70 Jan 11 Ocumension Therapeutics Announces First Patient Enrolled in the Phase III Clinical Trial of OT-1001 (Zerviate) in China
New 90-day high: HK$26.75 Dec 17
Ocumension Therapeutics Initiates the Real World Study of Its Core Product, OT-401 (YUTIQ) in Boao Super Hospital in Hainan Province, China Dec 02
Ocumension Therapeutics Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial Oct 27
New 90-day low: HK$22.30 Oct 22
Ocumension Therapeutics Receives Approval from China’S Center for Drug Evaluation of the National Medical Products Administration Sep 22
Ocumension Therapeutics to Report First Half, 2020 Results on Aug 26, 2020 Aug 18 Hissedar Getirileri 1477 HK Pharmaceuticals HK Pazar 7D -5.0% 0.2% 1.5% 1Y -34.7% -3.7% 20.6%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 1477 geçen yıl % -3.7 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: 1477 geçen yıl % 20.6 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 1477's price volatile compared to industry and market? 1477 volatility 1477 Average Weekly Movement 8.6% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.0%
İstikrarlı Hisse Senedi Fiyatı: 1477 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 1477 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Ocumension Therapeutics, iştirakleri ile birlikte Çin Halk Cumhuriyeti'nde bir oftalmik ilaç platformu şirketi olarak faaliyet göstermektedir. Oftalmik hastalar için tedaviler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Portföyünde kronik enfeksiyöz olmayan üveit, blefarit, enfektif ve alerjik konjonktivit, diyabetik maküler ödem, kuru göz, glokom ve oküler hipertansiyon, postoperatif enflamasyon, koroidal neovaskülarizasyon, bakteriyel konjonktivit, retinitis pigmentosa, akut glokom, yaşa bağlı maküler dejenerasyon, kornea greft reddi, miyopi ve optik nörit tedavisine yönelik ürünler ve ilaçlar bulunmaktadır.
Daha fazla göster Ocumension Therapeutics Temel Bilgiler Özeti Ocumension Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 1477 temel i̇stati̇sti̇kler Piyasa değeri HK$3.60b Kazançlar(TTM ) -HK$343.47m Gelir(TTM ) HK$330.23m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 1477 gelir tablosu (TTM ) Gelir CN¥310.29m Gelir Maliyeti CN¥129.44m Brüt Kâr CN¥180.86m Diğer Giderler CN¥503.58m Kazançlar -CN¥322.73m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/25 04:32 Gün Sonu Hisse Fiyatı 2024/12/24 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Ocumension Therapeutics 6 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Yanyin Zhu China International Capital Corporation Limited Fang Quan China International Capital Corporation Limited Ziyi Chen Goldman Sachs
Göster 3 daha fazla analist 
